Ogm evaluated as a method for investigating abnormal nipt results due to its ability to detect chromosomal structural variations found in recurrent pregnancy loss

San diego, oct. 14, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of a peer-reviewed study evaluating optical genome mapping (ogm) as a method for investigating abnormal noninvasive prenatal testing (nipt) results because of its ability to accurately identify complex structural aberrations relevant to recurrent pregnancy loss and infertility.
BNGO Ratings Summary
BNGO Quant Ranking